In January 2017, the Indian media reported on an exceptional legal battle playing out before the Delhi High Court regarding a young lady suffering from multi-drug resistant tuberculosis, suing the Indian government for access to a new TB drug called bedaquiline that was supposed to be effective on TB patients resistant to all forms of drugs.
One of the six government hospitals authorised to administer the drug at the time had reportedly denied access to it on the grounds that the patient did not meet certain domicile requirements.
